Since RPA1 and RPA3 have been identified as potential radiotherapy targets for NPC [12, 17], we next sought to investigate whether pharmacologic inhibition of RPA exerts a radiosensitizing effect on NPC cells. Here, RPA3 is linked to nasopharyngeal carcinoma.